Evidence map›Paper›PMID 42109580›Full record

ArticleBioinformatics advances2026

Computational design of class II MHC binding peptide with sequence-based evolution information.

Ying Cao, Yuqing Li, Weitong Ren, Wenfei Li, Zhiqiang Yan

Abstract read
In one paragraph

Article in Bioinformatics advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ying CaoPostgraduate Training Base Alliance, Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China.
Yuqing LiZhejiang Key Laboratory of Soft Matter Biomedical Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang Province 325000, China.
Weitong RenZhejiang Key Laboratory of Soft Matter Biomedical Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang Province 325000, China.
Wenfei LiZhejiang Key Laboratory of Soft Matter Biomedical Materials, Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, Zhejiang Province 325000, China.ORCID https://orcid.org/0000-0003-2679-4075
Zhiqiang YanPostgraduate Training Base Alliance, Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China.ORCID https://orcid.org/0000-0003-3865-3229

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MHCII-peptide binding plays a vital role in immunology. MHCII molecules are primarily expressed on the surface of antigen presenting cells where they capture and present exogenous antigen peptides to helper T cells, thereby activating humoral and cellular immune responses. Designing artificial MHCII binding peptides mimicking native peptides is crucial for vaccine development. However, it is challenge to design artificial binding peptides with conventional structure-based methods since the structures of the peptides are highly flexible at unbound state. In this work, we trained Transformer neural network to design the artificial peptides with sequence-based evolutionary information including the frequency distribution of amino acids at each site and the joint frequency distribution between amino acid pairs extracted from multiple sequence alignment of native peptides. In light of accurate sequence-based scoring function and reliable AlphaFold3 for complex structure prediction, the designed artificial peptides were predicted to have comparable binding affinities as native peptides and high structural confidence (pLDDT > 90.0) when binding to MHCII. Our work establishes a paradigm for designing different kinds of functional peptides and will greatly provide significant assistance to biomedical researchers in the medical and industrial fields.

Identifiers

PMID42109580
PMCPMC13154412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.